用力肺活量预测抗MDA5阳性皮肌炎相关间质性肺病生存
本研究基于单中心衍生队列和多中心验证队列,纳入抗MDA5抗体阳性且ILD病程≤3个月的住院DM患者,建立并验证6个月全因死亡预测模型。基线FVC%三分类(≥50%、<50%、无法完成)可显著区分三个风险阶段,衍生队列死亡率分别为15.3%、46.8%、97.4%,验证队列为14.9%、58.3%、86.4%(均P<0.05)。
要点
- 基线FVC%三分类可区分抗MDA5阳性DM-ILD患者6个月死亡风险。
- FVC%<50%或无法完成者6个月死亡率显著升高。
- 该预测模型有助于临床风险分层和未来试验队列富集。
核心结论
- 基于FVC%的三分类预测因子在抗MDA5阳性DM-ILD中经验证有助于风险分层。
研究设计与样本
- 回顾性观察性研究,使用单中心衍生队列和多中心验证队列。
- 纳入住院DM患者,抗MDA5抗体阳性且入院时ILD病程≤3个月。
- 衍生队列184例,验证队列81例。
主要发现
- 衍生队列和验证队列6个月累积死亡率分别为40.8%和40.7%。
- FVC%三分类(≥50%、<50%、无法完成)在衍生队列中对应死亡率15.3%、46.8%、97.4%。
- 验证队列中对应死亡率为14.9%、58.3%、86.4%(均P<0.05)。
关键数值与推荐
- 预后因子为基线FVC%三分类:FVC%≥50%、FVC%<50%、无法完成。
- 最佳截断值由survminer R包确定。
临床怎么用
- 临床可依据基线FVC%对患者进行风险分层。
- 有助于识别高危患者并可能促进未来试验队列富集。
局限性
- 回顾性研究设计。
- 衍生队列为单中心。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Anti-melanoma differentiation-associated gene 5 (MDA5) positive DM is a life-threatening disease often complicated with rapidly progressive interstitial lung disease (ILD). This study aimed to establish and validate a clinical prediction model for 6-month all-cause mortality in Chinese patients with anti-MDA5 positive DM-ILD. METHODS: We conducted a retrospective observational study using a single-centre derivation cohort and a multicentre validation cohort. Hospitalized DM patients with positive anti-MDA5 antibody and ILD course ≤3 months on admission were included. Patients' baseline characteristics were described and compared between the deceased and survivors by univariable Cox regression. Optimal cut-off values were defined by the 'survminer' R package for significant continuous variables. Independent prognostic factors were determined by the final multivariable Cox regression model chosen by backward stepwise algorithm, which could be reproduced in both cohorts. The Kaplan-Meier survival analyses based on the derived predictor were conducted. RESULTS: A total of 184 and 81 eligible patients were included with a cumulative 40.8 and 40.7% 6-month mortality in the derivation and validation cohorts, respectively. Based on multivariable Cox regression, the prognostic factor at baseline was identified and validated as three-category forced vital capacity (FVC)%: FVC% ≥50%, FVC% <50%, unable to perform. This significantly distinguishes three risk stages with mortalities of 15.3, 46.8, 97.4% in the derivation cohort, and 14.9, 58.3, 86.4 in the validation cohort, respectively (all P <0.05). CONCLUSION: The validated FVC%-based categorical predictor in anti-MDA5 positive DM-ILD is helpful for risk stratification in clinical practice and might facilitate cohort enrichment for future trials.
引用
- Wu W, Xu W, Sun W, et al. Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: a multi-centre cohort study. Rheumatology (Oxford). 2021. PMID: 33764398. doi:10.1093/rheumatology/keab305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。